Since the p.Glu15Lys ANGPTL4 allele lowers susceptibility to ASCVD by reducing repression of LPL activity, ANGPTL4 might seem to be a promising target for therapeutic management of dyslipidemia. Here, ANGPTL4 is linked to metabolic syndrome.